Does pharmacological blockade of S100A8/A9 with ABR-238901 mitigate myocardial dysfunction and inflammation in severe sepsis?
Pharmacological blockade of S100A8/A9 with ABR-238901 mitigates myocardial dysfunction and inflammation, representing a potential novel therapeutic strategy for severe sepsis.
Elevated S100A8/A9 is associated with the development of LV dysfunction in severe sepsis patients and in a mouse model of endotoxemia. Pharmacological blockade of S100A8/A9 with ABR-238901 has potent anti-inflammatory effects, mitigates myocardial dysfunction and might represent a novel therapeutic strategy for patients with severe sepsis.
Jakobsson et al. (Fri,) studied this question.